MEA Cardiac Safety Services Market - Industry Trends and Forecast to 2029

TABLE OF CONTENT

TABLE OF CONTENTS 1 INTRODUCTION 26 1.1 OBJECTIVES OF THE STUDY 26 1.2 MARKET DEFINITION 26 1.3 OVERVIEW OF MIDDLE EAST & AFRICA CARDIAC SAFETY SERVICES MARKET 26 1.4 LIMITATIONS 27 1.5 MARKETS COVERED 28 2 MARKET SEGMENTATION 30 2.1 MARKETS COVERED 30 2.2 GEOGRAPHICAL SCOPE 31 2.3 YEARS CONSIDERED FOR THE STUDY 32 2.4 CURRENCY AND PRICING 32 2.5 DBMR TRIPOD DATA VALIDATION MODEL 33 2.6 MULTIVARIATE MODELLING 36 2.7 SERVICES LIFELINE CURVE 36 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 37 2.9 DBMR MARKET POSITION GRID 38 2.10 MARKET END USER GRID 40 2.11 VENDOR SHARE ANALYSIS 41 2.12 SECONDARY SOURCES 42 2.13 ASSUMPTIONS 42 3 EXECUTIVE SUMMARY 43 4 PREMIUM INSIGHTS 46 4.1 PORTERS FIVE FORCES 47 4.2 PESTEL ANALYSIS 48 5 EPIDEMIOLOGY 49 5.1 INCIDENCE OF ALL BY GENDER 49 5.2 TREATMENT RATE 50 5.3 MORTALITY RATE 50 5.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL 51 6 INDUSTRY INSIGHT 52 6.1 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES 52 6.2 PATENT ANALYSIS 53 6.3 PATENT FLOW DIAGRAM 54 6.4 KEY PATIENT ENROLLMENT STRATEGIES 54 6.5 PRICING STRATEGY 57 7 MIDDLE EAST & AFRICA CARDIAC SAFETY SERVICES MARKET: REGULATIONS 58 8 MARKET OVERVIEW 61 8.1 DRIVERS 63 8.1.1 INCREASE IN THE NUMBER OF CLINICAL TRIALS 63 8.1.2 INCREASE IN HEALTHCARE EXPENDITURE AND FUNDING 63 8.1.3 INCREASE IN STRATEGIC INITIATIVES BY MAJOR MARKET PLAYERS 64 8.1.4 INCREASE IN R&D ACTIVITIES 64 8.2 RESTRAINTS 65 8.2.1 HIGH COST OF CARDIAC SAFETY EVALUATION 65 8.2.2 STRICT REGULATORY 65 8.3 OPPORTUNITIES: 66 8.3.1 INCREASE IN NEW DRUG DEVELOPMENT 66 8.3.2 RISE IN THE EXPANSION OF THE CARDIAC SAFETY SERVICES 67 8.4 CHALLENGES 67 8.4.1 TIME-CONSUMING PROCEDURE 67 8.4.2 LACK OF SKILLED PERSON TO OPERATE DEVICES DURING CARDIAC SAFETY EVALUATION 68 9 MIDDLE EAST & AFRICA CARDIAC SAFETY SERVICES MARKET, BY SERVICES 69 9.1 OVERVIEW 70 9.2 ECG/HOLTER MEASUREMENTS 74 9.3 BLOOD PRESSURE MEASUREMENTS 74 9.4 IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES 75 9.4.1 HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS 76 9.4.1.1 1 CONCENTRATIONS 76 9.4.1.2 4 CONCENTRATIONS 76 9.4.2 COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) 77 9.4.2.1 3 CONCENTRATIONS 77 9.4.2.2 5 CONCENTRATIONS 77 9.4.3 IN VITRO HERG ASSAY 77 9.4.4 OTHERS 77 9.5 CARDIOVASCULAR IMAGING 77 9.6 REAL TIME TELEMETRY MONITORING 78 9.7 CENTRAL OVER-READ OF ECGS 79 9.8 NON-INVASIVE CARDIAC IMAGING 79 9.9 PHYSIOLOGIC STRESS TESTING 80 9.10 THOROUGH QT STUDIES 81 9.11 TQT AND EXPOSURE RESPONSE MODELLING 81 9.12 PLATELET AGGREGATION 82 9.13 OTHERS 83 10 MIDDLE EAST & AFRICA CARDIAC SAFETY SERVICES MARKET, BY PHASE 84 10.1 OVERVIEW 85 10.2 PHASE I 88 10.3 PHASE II 88 10.4 PHASE III 89 11 MIDDLE EAST & AFRICA CARDIAC SAFETY SERVICES MARKET, BY TYPE 90 11.1 OVERVIEW 91 11.2 INTEGRATED SERVICES 94 11.3 STANDALONE SERVICES 95 12 MIDDLE EAST & AFRICA CARDIAC SAFETY SERVICES MARKET, BY END USER 96 12.1 OVERVIEW 97 12.2 PHARMACEUTICALS & BIOPHARMACEUTICALS COMPANIES 100 12.3 CONTRACT RESEARCH ORGANIZATIONS 100 12.4 ACADEMIC AND RESEARCH INSTITUTE 101 13 MIDDLE EAST & AFRICA CARDIAC SAFETY SERVICES MARKET, BY REGION 102 13.1 MIDDLE EAST AND AFRICA 103 13.1.1 SOUTH AFRICA 111 13.1.2 SAUDI ARABIA 114 13.1.3 U.A.E. 117 13.1.4 ISRAEL 120 13.1.5 EGYPT 123 13.1.6 REST OF MIDDLE EAST AND AFRICA 126 14 MIDDLE EAST & AFRICA CARDIAC SAFETY SERVICES MARKET: COMPANY LANDSCAPE 127 14.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA 127 15 COMPANY PROFILE 128 15.1 EUROFINS SCIENTIFIC 128 15.1.1 COMPANY SNAPSHOT 128 15.1.2 REVENUE ANALYSIS 129 15.1.3 COMPANY SHARE ANALYSIS 129 15.1.4 PRODUCT PORTFOLIO 129 15.1.5 RECENT DEVELOPMENTS 130 15.1.5.1 AGREEMENTS 130 15.1.5.2 ACQUISITION 130 15.2 PPD INC. (SUBSIDIARY OF THERMO FISHER SCIENTIFIC INC) 131 15.2.1 COMPANY SNAPSHOT 131 15.2.2 REVENUE ANALYSIS 131 15.2.3 COMPANY SHARE ANALYSIS 132 15.2.4 PRODUCT PORTFOLIO 132 15.2.5 RECENT DEVELOPMENT 132 15.2.5.1 INVESTMENT 132 15.3 KONINKLIJKE PHILIPS N.V. 133 15.3.1 COMPANY SNAPSHOT 133 15.3.2 REVENUE ANALYSIS 133 15.3.3 COMPANY SHARE ANALYSIS 134 15.3.4 PRODUCT PORTFOLIO 134 15.3.5 RECENT DEVELOPMENT 134 15.3.5.1 ACQUISITION 134 15.4 IQVIA 135 15.4.1 COMPANY SNAPSHOT 135 15.4.2 REVENUE ANALYSIS 135 15.4.3 COMPANY SHARE ANALYSIS 136 15.4.4 PRODUCT PORTFOLIO 136 15.4.5 RECENT DEVELOPMENTS 136 15.4.5.1 ACQUISITION 136 15.5 LABORATORY CORPORATION OF AMERICA HOLDINGS 137 15.5.1 COMPANY SNAPSHOT 137 15.5.2 REVENUE ANALYSIS 137 15.5.3 COMPANY SHARE ANALYSIS 138 15.5.4 PRODUCT PORTFOLIO 138 15.5.5 RECENT DEVELOPMENTS 138 15.5.5.1 NEW LABORATORY 138 15.5.5.2 ACQUISITION 138 15.6 BANOOK 139 15.6.1 COMPANY SNAPSHOT 139 15.6.2 PRODUCT PORTFOLIO 139 15.6.3 RECENT DEVELOPMENT 139 15.6.3.1 AGREEMENT 139 15.7 BIOTRIAL 140 15.7.1 COMPANY SNAPSHOT 140 15.7.2 PRODUCT PORTFOLIO 140 15.7.3 RECENT DEVELOPMENT 140 15.7.3.1 NEW CENTER OPENING 140 15.8 CELERION 141 15.8.1 COMPANY SNAPSHOT 141 15.8.2 PRODUCT PORTFOLIO 141 15.8.3 RECENT DEVELOPMENT 141 15.8.3.1 NEW CENTER OPENING 141 15.9 CERTARA 142 15.9.1 COMPANY SNAPSHOT 142 15.9.2 REVENUE ANALYSIS 142 15.9.3 PRODUCT PORTFOLIO 143 15.9.4 RECENT DEVELOPMENTS 143 15.9.4.1 CONTRACT 143 15.9.4.2 ACQUISITION 143 15.10 CLARIO 144 15.10.1 COMPANY SNAPSHOT 144 15.10.2 PRODUCT PORTFOLIO 144 15.10.3 RECENT DEVELOPMENT 144 15.10.3.1 PRODUCT EXPANSION 144 15.11 MEDPACE 145 15.11.1 COMPANY SNAPSHOT 145 15.11.2 REVENUE ANALYSIS 145 15.11.3 PRODUCT PORTFOLIO 146 15.11.4 RECENT DEVELOPMENTS 146 15.11.4.1 ACQUISITION 146 15.12 NCARDIA 147 15.12.1 COMPANY SNAPSHOT 147 15.12.2 PRODUCT PORTFOLIO 147 15.12.3 RECENT DEVELOPMENT 147 15.12.3.1 PARTNERSHIP 147 15.13 NEXEL CO., LTD 148 15.13.1 COMPANY SNAPSHOT 148 15.13.2 PRODUCT PORTFOLIO 148 15.13.3 RECENT DEVELOPMENTS 148 15.13.3.1 JOINT VENTURE 148 15.13.3.2 PARTNERSHIP 149 15.14 PHYSIOSTIM 150 15.14.1 COMPANY SNAPSHOT 150 15.14.2 PRODUCT PORTFOLIO 150 15.14.3 RECENT DEVELOPMENT 150 15.14.3.1 PARTNERSHIP 150 15.15 RICHMOND PHARMACOLOGY 151 15.15.1 COMPANY SNAPSHOT 151 15.15.2 PRODUCT PORTFOLIO 151 15.15.3 RECENT DEVELOPMENT 151 15.15.3.1 EVENT 151 15.16 SGS SA 152 15.16.1 COMPANY SNAPSHOT 152 15.16.2 REVENUE ANALYSIS 152 15.16.3 PRODUCT PORTFOLIO 153 15.16.4 RECENT DEVELOPMENT 153 15.16.4.1 ACQUISITION 153 15.17 SHANGHAI MEDICILON INC. 154 15.17.1 COMPANY SNAPSHOT 154 15.17.2 PRODUCT PORTFOLIO 154 15.17.3 RECENT DEVELOPMENTS 154 15.17.3.1 PARTNERSHIP 154 15.17.3.2 PARTNERSHIP 155 16 QUESTIONNAIRE 156 17 RELATED REPORTS 158